ACELYRIN announced the appointment of Shephard Mpofu, MD, MRCP, FRCP as Senior Vice President of Development. Dr. Mpofu will be responsible for leading clinical development as well as translational sciences and will also join the company’s Senior Leadership Team. Dr. Mpofu joins ACELYRIN after nearly 20 years at Novartis AG, where he most recently served as Chief Medical Officer for its Gene Therapy Franchise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLRN:
- Zura Bio’s approach could be ‘promising’ in HS, says Guggenheim
- Acelyrin downgraded to Equal Weight from Overweight at Morgan Stanley
- MoonLake faces less competition after Acelyrin failure, says Guggenheim
- Acelyrin (NASDAQ: SLRN) Plummets on Disappointing HS Trial Results
- Acelyrin pullback on izokibep data a buying opportunity, says Piper Sandler
